Leo Pharma expects new FDA ruling for eczema treatment tralokinumab in early 2022
![Photo: Leo Pharma / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13327341.ece/ALTERNATES/schema-16_9/doc7hrglmdiwdd500ls650.jpg)
As Leo Pharma rolls out eczema treatment tralokinumab in Europe under the name of Adtralza, it is waiting for a new ruling on the same drug in the US, where it was denied marketing approval last year.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.